MX2020007246A - Diseño de vacuna integral para el avance de enfermedad comensal. - Google Patents

Diseño de vacuna integral para el avance de enfermedad comensal.

Info

Publication number
MX2020007246A
MX2020007246A MX2020007246A MX2020007246A MX2020007246A MX 2020007246 A MX2020007246 A MX 2020007246A MX 2020007246 A MX2020007246 A MX 2020007246A MX 2020007246 A MX2020007246 A MX 2020007246A MX 2020007246 A MX2020007246 A MX 2020007246A
Authority
MX
Mexico
Prior art keywords
commensal
disease progression
vaccine design
comprehensive vaccine
comprehensive
Prior art date
Application number
MX2020007246A
Other languages
English (en)
Inventor
Charles Jones
Blaine PFEIFFER
Original Assignee
Univ New York State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York State Res Found filed Critical Univ New York State Res Found
Publication of MX2020007246A publication Critical patent/MX2020007246A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/625—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier binding through the biotin-streptavidin system or similar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Abstract

Se proporcionan métodos y compuestos de vacuna contra la Streptococcus pneumoniae. El compuesto comprende liposomas que tienen polisacáridos de uno o más serotipos y tienen proteínas unidas de forma no covalente a la superficie y expuestas al exterior.
MX2020007246A 2017-10-13 2018-10-12 Diseño de vacuna integral para el avance de enfermedad comensal. MX2020007246A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762572081P 2017-10-13 2017-10-13
US201862670419P 2018-05-11 2018-05-11
PCT/US2018/055676 WO2019075372A1 (en) 2017-10-13 2018-10-12 COMPREHENSIVE VACCINE DESIGN AGAINST THE PROGRESSION OF COMMENSITY DISEASES

Publications (1)

Publication Number Publication Date
MX2020007246A true MX2020007246A (es) 2020-11-13

Family

ID=66101685

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007246A MX2020007246A (es) 2017-10-13 2018-10-12 Diseño de vacuna integral para el avance de enfermedad comensal.

Country Status (8)

Country Link
US (1) US11541110B2 (es)
EP (1) EP3694490B1 (es)
JP (1) JP2020536968A (es)
CN (1) CN111479558A (es)
CA (1) CA3079111A1 (es)
MX (1) MX2020007246A (es)
TW (1) TW201929896A (es)
WO (1) WO2019075372A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ515041A (en) 1999-04-21 2004-03-26 Powderject Vaccines Inc Nucleic acid immunization
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
US20020122820A1 (en) 2001-01-16 2002-09-05 Hildebrand William H. Soluble MHC artificial antigen presenting cells
US7005139B2 (en) 2001-04-05 2006-02-28 Hong Kong University Of Science And Technology Compositions and methods for the targeted delivery of agents to treat liver cancer
WO2006009825A1 (en) 2004-06-17 2006-01-26 Virun, Inc. Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents
EP1928419A1 (en) 2005-09-30 2008-06-11 Lipoxen Technologies Limited Multivalent liposomal vaccine compositions comprising polysaccharide antigens and a protein adjuvant
CN101024079B (zh) 2006-02-17 2012-02-01 福州昌晖生物工程有限公司 肺炎链球菌多糖-外膜蛋白结合疫苗及制备方法
AU2007284878B2 (en) 2006-08-07 2013-01-17 President And Fellows Of Harvard College Protein matrix vaccines and methods of making and administering such vaccines
KR20110068831A (ko) 2009-12-16 2011-06-22 재단법인 전라남도생물산업진흥재단 리포좀 조성물, 그 제조방법, 및 폐렴 백신으로서의 그 용도
WO2011103588A1 (en) 2010-02-22 2011-08-25 Liquidia Technologies, Inc. Polysaccharide particle vaccines
US9289488B2 (en) 2010-08-12 2016-03-22 Ac Immune Sa Vaccine engineering
EP2709603B1 (en) 2011-05-11 2021-03-24 Children's Medical Center Corporation Modified biotin-binding protein, fusion proteins thereof and applications
US9724401B2 (en) 2011-05-18 2017-08-08 Matrivax, Inc. Protein matrix vaccine compositions including polycations
KR101778169B1 (ko) 2012-04-11 2017-09-13 리폭센 테크놀로지즈 리미티드 미엘린염기성단백질의 올리고펩티드 단편을 함유하는 리포솜, 의약조성물 및 다발성경화증의 치료법
GB201518684D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
US11103568B2 (en) * 2016-04-05 2021-08-31 The Research Foundation For The State University Of New York Pneumococcal vaccine formulations

Also Published As

Publication number Publication date
US20200376108A1 (en) 2020-12-03
CA3079111A1 (en) 2019-04-18
CN111479558A (zh) 2020-07-31
EP3694490B1 (en) 2024-03-20
TW201929896A (zh) 2019-08-01
EP3694490A4 (en) 2021-08-18
JP2020536968A (ja) 2020-12-17
US11541110B2 (en) 2023-01-03
WO2019075372A1 (en) 2019-04-18
EP3694490A1 (en) 2020-08-19

Similar Documents

Publication Publication Date Title
ZA201903620B (en) Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
MX2016009469A (es) Polisacaridos capsulares de streptococcus pneumoniae y conjugados de los mismos.
SG10201803042PA (en) Anti-tim-3 antibodies
WO2016094837A3 (en) Anti-c10orf54 antibodies and uses thereof
WO2016019134A8 (en) Flagellin-based agents and uses including effective vaccination
CY1124425T1 (el) Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης
WO2014197871A3 (en) Antibody-drug conjugates, compositions and methods of use
WO2015117008A3 (en) Broadly neutralizing anti-hiv antibodies and epitope therefor
WO2016014434A3 (en) Anti-cd74 antibodies, compositions comprising anti-cd74 antibodies and methods of using anti-cd74 antibodies
PH12021550690A1 (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
HK1256414A1 (zh) 新穎醣類抗體、醫藥組成物及其用途
EP3790591A4 (en) COMPOSITIONS AND METHODS RELATED TO ANTI-CD19 ANTIBODY-DRUG CONJUGATES
JO3155B1 (ar) معدِّل نكهة حلوة
WO2017214458A3 (en) Anti-cd98 antibodies and antibody drug conjugates
WO2017214462A3 (en) Anti-cd98 antibodies and antibody drug conjugates
MX2019004690A (es) Constructos de anticuerpos.
AU2013331781A8 (en) Immunogenic composition comprising 1 or more Streptococcus pneumoniae capsular saccharide conjugates and a protein component comprising Protein E and/or PilA from Haemophilus influenzae.
MX2017008390A (es) Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato.
NZ742805A (en) Anti-cd22 antibody-maytansine conjugates and methods of use thereof
MX2019005855A (es) Formulaciones que se pueden pulverizar.
WO2016116882A3 (en) Novel compositions of carfilzomib
EP3810170A4 (en) METHODS AND COMPOSITIONS RELATING TO A NEXT GENERATION VACCINE
MX2016000099A (es) Vacunas sinteticas contra streptococcus pneumoniae tipo 1.
WO2016198170A8 (en) Vaccines against streptococcus pneumoniae serotype 5